BOTHELL, WA, and VANCOUVER, Dec. 4 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc (NASDAQ: OGXI) will participate on the 'Waging a Battle Against Cancer' panel at the RBC Capital Markets 2008 Healthcare Conference on Thursday, December 11 at 8:00 am ET at the Westin Times Square Hotel in New York. During the panel discussion, OncoGenex' President and Chief Executive Officer, Scott Cormack, will provide a brief overview of the company's oncology drug pipeline and its approach for addressing cancer treatment resistance.
A live webcast of the panel will be available on the Events section of the Investor Relations page of the company Web site at www.oncogenex.com. A replay of the webcast will be available for 30 days following the event.
About OncoGenex Pharmaceuticals
OncoGenex Pharmaceuticals is a biopharmaceutical company committed to the development and commercialization of new cancer therapies that address unmet needs in the treatment of cancer. OncoGenex has a deep oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OGX-011, the lead candidate currently completing five Phase 2 clinical studies in prostate, lung and breast cancers, is designed to inhibit the production of a specific protein associated with treatment resistance; OGX-427 and SN2310 are in Phase 1 clinical development; and CSP-9222 and OGX-225 are currently in pre-clinical development. More information is available at www.oncogenex.com.
|SOURCE OncoGenex Pharmaceuticals, Inc.|
Copyright©2008 PR Newswire.
All rights reserved